|Bid||0.0000 x 1000|
|Ask||0.0000 x 1200|
|Day's Range||4.2350 - 4.4700|
|52 Week Range||2.4000 - 5.7900|
|Beta (5Y Monthly)||1.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.61|
Amneal Pharmaceuticals (AMRX) closed at $4.36 in the latest trading session, marking a -1.13% move from the prior day.
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Aclaris (ACRS) initiates a phase IIa study on ATI-1777, for the treatment of moderate-to-severe atopic dermatitis.